Trial reportBritish journal of clinical pharmacology2013
Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.
Trial report in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.Clinical and translational science · 2020Trial
- Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout.Arthritis care & research · 2026Article
- Evaluation of Xanthine Oxidase Inhibitors Febuxostat and Allopurinol on Kidney Dysfunction and Histological Damage in Two-Kidney, One-Clip (2K1C) Rats.Scientifica · 2025Article
- A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol.Journal of personalized medicine · 2024Article
- Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout.Journal of inflammation research · 2024Article
- Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.British journal of clinical pharmacology · 2023Article
- Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.British journal of clinical pharmacology · 2022Article
- Critical appraisal of serum urate targets in the management of gout.Nature reviews. Rheumatology · 2022Review
- Honorary Professor Garry Graham.Inflammopharmacology · 2021Article
- Better outcomes for patients with gout.Inflammopharmacology · 2020Article
- Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.Current rheumatology reports · 2018Review
- Individualising the dose of allopurinol in patients with gout.British journal of clinical pharmacology · 2017Observational
- Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.Clinical pharmacokinetics · 2017Review
- ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.The pharmacogenomics journal · 2017Article
- Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.Arthritis & rheumatology (Hoboken, N.J.) · 2017Review
- Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine.Clinical rheumatology · 2016Article
- The management of gout.Australian prescriber · 2016Review
- Predicting allopurinol response in patients with gout.British journal of clinical pharmacology · 2016Article
- Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.Seminars in arthritis and rheumatism · 2014Review
- Editors' pick 2013.British journal of clinical pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of the study was to identify and quantify factors that control the plasma concentrations of urate during allopurinol treatment and to predict optimal doses of allopurinol.
methodsPlasma concentrations of urate and creatinine (112 samples, 46 patients) before and during treatment with various doses of allopurinol (50-600 mg daily) were monitored. Non-linear and multiple linear regression equations were used to examine the relationships between allopurinol dose (D), creatinine clearance (CLcr) and plasma concentrations of urate before (UP) and during treatment with allopurinol (UT).
resultsPlasma concentrations of urate achieved during allopurinol therapy were dependent on the daily dose of allopurinol and the plasma concentration of urate pre-treatment. The non-linear equation: UT = (1 - D/(ID50 + D)) × (UP - UR) + UR , fitted the data well (r(2) = 0.74, P < 0.0001). The parameters and their best fit values were: daily dose of allopurinol reducing the inhibitable plasma urate by 50% (ID50 = 226 mg, 95% CI 167, 303 mg), apparent resistant plasma urate (UR = 0.20 mmol l(-1), 95 % CI 0.14, 0.25 mmol l(-1)). Incorporation of CLcr did not significantly improve the fit (P = 0.09).
conclusionsA high baseline plasma urate concentration requires a high dose of allopurinol to reduce plasma urate below recommended concentrations. This dose is dependent on only the pre-treatment plasma urate concentration and is not influenced by CLcr .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.